Clinical Trial Update: Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 trial evaluating AZD6765 in depressed adults, comparing MRI effects of the drug to placebo.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• AZD6765 (lanicemine)

Snippet

Sponsor: AstraZeneca | Conditions: Depression | Phase 1 | Status: COMPLETED